CCAT2 and ovarian cancer: Among 1680 patients with ovarian cancers, about 185 cases (11%) have the alterations in CCAT2 and 588 cases (35%) have the alterations in MYC (Figure 1C), indicating a high incidence of the aberrant expression of CCAT2 and MYC in ovarian epithelial carcinomas.